Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

1.9%

28 terminated/withdrawn out of 1513 trials

Success Rate

91.6%

+5.1% vs industry average

Late-Stage Pipeline

15%

227 trials in Phase 3/4

Results Transparency

5%

14 of 305 completed trials have results

Key Signals

359 recruiting14 with results19 terminated9 withdrawn

Enrollment Performance

Analytics

Phase 2
576(49.3%)
N/A
268(22.9%)
Phase 3
184(15.7%)
Phase 1
91(7.8%)
Phase 4
43(3.7%)
Early Phase 1
7(0.6%)
1169Total
Phase 2(576)
N/A(268)
Phase 3(184)
Phase 1(91)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1513)

Showing 20 of 1513 trials
NCT05384444Not ApplicableActive Not Recruiting

Effect of FMD on Colorectal Cancer Patients

Role: lead

NCT07013461Recruiting

International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer

Role: collaborator

NCT07562659Phase 2Recruiting

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

Role: lead

NCT07562711Phase 2Recruiting

Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer

Role: lead

NCT07562503Phase 2Recruiting

Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer

Role: lead

NCT07562490Phase 2Recruiting

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

Role: lead

NCT07561060Phase 1Recruiting

Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

Role: lead

NCT07557849Not Yet Recruiting

Multicentric Database for KRAS Mutant Pancreatic Cancer

Role: lead

NCT07451795Phase 2Recruiting

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Role: lead

NCT07532122Completed

Postoperative Anxiety and Depression Among Chinese Elderly Patients

Role: collaborator

NCT07555678Phase 2Recruiting

Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase

Role: lead

NCT07557654Not Yet Recruiting

Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT

Role: lead

NCT06613633Completed

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Role: lead

NCT07554846Phase 3Not Yet Recruiting

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

Role: lead

NCT06572722Phase 2Withdrawn

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Role: lead

NCT07441369Phase 2Enrolling By Invitation

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

Role: lead

NCT02633514Phase 3Withdrawn

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Role: lead

NCT06402708Phase 3Recruiting

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Role: lead

NCT06597227Not ApplicableRecruiting

Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy

Role: collaborator

NCT06401447Not ApplicableActive Not Recruiting

TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

Role: lead